Prior Authorization Required

Precertification and prior authorization are required for intravenous abatacept (Orencia IV). For precertification of Orencia IV, contact Aetna at (866) 752-7021 or fax (888) 267-3277 and submit the Statement of Medical Necessity (SMN) / prior authorization documentation per plan procedures. Clinical Policy Bulletins (CPBs) and specific plan procedures govern coverage determinations — CPBs assist in administering benefits but do not guarantee coverage or substitute for clinical judgment.

• Precertification contact: (866) 752-7021; fax: (888) 267-3277.
• Submit Statement of Medical Necessity (SMN) or equivalent prior authorization form as required by plan.

Indication, Dosing and Transplant Context

Document the requested FDA-approved indication or recognized compendial use, including specific indication, dosing, and transplant context (when applicable). For transplant-related indications (eg, aGVHD prophylaxis), include transplant details: donor type, transplant date, conditioning regimen, and concurrent prophylactic immunosuppression.

• Indication (FDA-approved or compendial) and intended dosing regimen.
• For HSCT: donor type (matched/1-allele mismatch), transplant date, and concurrent CNI/MTX use.

Indication, Age/Weight and Prior Therapy

Provide the member’s age and weight (for pediatric dosing), prior therapy history, and specific details of prior treatment failures, contraindications or intolerance to alternatives. When required by brand-step rules, document trials of specified alternative targeted immune modulators and duration of each trial (eg, one-month trials of specified lower-cost alternatives for certain RA and PsA indications).

• Age and weight (include for pediatric dosing calculations).
• List prior DMARDs, targeted therapies, and duration of trials with outcomes (ineffective, intolerance, or contraindication).
• When brand-step applies, document trials of listed less-costly targeted immune modulators and reasons for failure or exception.

Prior Authorization for Off‑Label / Refractory and Small‑Study Indications

Prior authorization is expected for off‑label, refractory, or small-study indications. Requests for indications supported only by small case series, open-label studies, or single-arm reports (eg, granulomatosis with polyangiitis, RA‑ILD, localized scleroderma, nephrotic syndrome/TRNS, other rare uses) must include a clinical justification and supporting evidence (published studies, trial data, or rationale). Limited or low-quality evidence may lead to denial.

• Attach relevant publications, study summaries, or trial protocols supporting the request.
• Explain why standard therapies are inappropriate or have failed.
• Note that small-study evidence (case series, open‑label, n<=20 etc.) may be insufficient and may result in denial.

Documentation Required for Off‑Label Use

When requesting coverage for off‑label abatacept use, include detailed clinical documentation: diagnosis with ICD‑10 code, prior treatments and durations, objective measures of disease activity, prior randomized trial evidence if available, and the clinical rationale for using abatacept. Cite supporting references and any relevant trial data.

• Diagnosis and relevant ICD‑10 codes (note: some ICD‑10 codes are listed as not covered for CPB indications).
• Prior treatment history with dates and outcomes; objective labs/imaging and disease activity scores where applicable.
• Relevant randomized trial data or structured evidence summaries, and bibliographic references.

ICD‑10 and Coverage

ICD‑10 diagnoses: verify that the submitted diagnosis is covered under this CPB. Some ICD‑10 codes are explicitly listed as not covered for indications in this CPB (not all‑inclusive); include alternate supporting documentation if the requested use is a compendial or FDA‑approved indication.

• Check coding table for covered vs not‑covered ICD‑10 codes before submission.
• If diagnosis appears in the CPB not‑covered list, provide justification or alternative diagnosis supported by documentation.

Prior DMARD Trial Documentation and Step‑Therapy Context

Provide trial evidence and a complete treatment history for the condition being treated. For FDA‑approved indications where labeling or clinical guidelines recommend prior DMARD trials, document prior DMARD (eg, methotrexate, leflunomide) use and reasons to avoid them per Appendix A (eg, pregnancy, liver disease, drug interaction, intolerance).

• Document prior DMARD trials, durations, and outcomes (ineffective, intolerant, contraindicated).
• If bypassing step therapy, document a clinical reason from Appendix A to avoid methotrexate or leflunomide.

Clinical Policy Bulletin and Plan Procedures

Aetna uses Clinical Policy Bulletins (CPBs) and plan procedures to determine coverage. CPBs provide clinical guidance and administration rules but do not guarantee coverage. Participating providers remain responsible for clinical management.

• Refer to the applicable CPB and plan-specific procedures for coverage rules.
• CPBs are administrative aids and do not replace clinical judgement.

Authorization Decision Notes and Denial Risk

Be aware that there are no single, specific authorization triggers contained in this section beyond the general requirements above; authorization determinations are made based on whether submitted documentation meets the CPB criteria and plan procedures. If documentation is incomplete or evidence is limited, the request may be denied.

• Incomplete prior‑therapy documentation, missing age/weight, or absent transplant details may delay or result in denial.
• Limited evidence for the requested indication increases risk of denial.